Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
Michael Ament(Post Apotheke), Sheena K. Aurora(Impel Neuropharma (United States)), Mallikarjuna Rettiganti(Eli Lilly (United States)), Virginia L. Stauffer(Eli Lilly (United States)), Kathleen A. Day(Eli Lilly (United States)), Vladimir Skljarevski(Eli Lilly (United States)), Eric Pearlman(University of California, San Francisco)
Cited by 43
Related Papers
Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia
|The Journal of Experimental Medicine|1997|532
CGRP and the Trigeminal System in Migraine
|Headache The Journal of Head and Face Pain|2019|483
N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis
|Nature Communications|2020|453
Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP
|Nature Communications|2016|446